Trials / Unknown
UnknownNCT06044844
Effectiveness of Tofacitinib in Systemic Sclerosis
A Study Evaluating the Effectiveness of Tofacitinib in Systemic Sclerosis
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to compare efficacy of tofacitinib with cyclophosphamide in skin thickening in early diffuse cutaneous systemic sclerosis .
Detailed description
compare tofacitinib 5mg twice daily with cyclophosphamide 500mg/m2/month in early diffuse cutaneous systemic sclerosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tofacitinib | tofacitinib efficacy |
Timeline
- Start date
- 2023-11-01
- Primary completion
- 2024-05-01
- Completion
- 2024-05-01
- First posted
- 2023-09-21
- Last updated
- 2023-09-21
Locations
1 site across 1 country: Bangladesh
Source: ClinicalTrials.gov record NCT06044844. Inclusion in this directory is not an endorsement.